Gomez Christopher S, Gomez Pablo, Knapp Judith, Jorda Merce, Soloway Mark S, Lokeshwar Vinata B
Department of Urology, University of Miami Miller School of Medicine, Miami, Florida 33101, USA.
J Urol. 2009 Oct;182(4):1350-6. doi: 10.1016/j.juro.2009.06.070. Epub 2009 Aug 14.
Molecular markers could aid prostate specific antigen, biopsy Gleason sum and clinical stage to provide accurate information on prostate cancer progression. HYAL-1 hyaluronidase and hyaluronic acid staining in prostatectomy specimens predicts biochemical recurrence. We examined whether hyaluronic acid and HYAL-1 staining in biopsy specimens predicts biochemical recurrence and correlates with staining in matched prostatectomy specimens.
Biopsy and prostatectomy specimens were obtained from 61 patients with clinically localized prostate cancer from multiple centers, including 23 with (group 1) and 38 without (group 2) biochemical recurrence. Mean followup was 103.1 months. Biotinylated hyaluronic acid binding protein and anti-HYAL-1 antibody were used for hyaluronic acid and HYAL-1 staining, respectively. Staining was graded between 0 and 300 depending on staining intensity and area.
HYAL-1 and hyaluronic acid were expressed in tumor cells and stroma, respectively. In biopsy specimens HYAL-1 and hyaluronic acid expression was higher in group 1 than in group 2 (203.9 and 182.1 vs 48.8 and 87.0, respectively, p <0.0001). On univariate analysis hyaluronic acid, HYAL-1, biopsy Gleason and prostate specific antigen significantly predicted biochemical recurrence (p <0.001). On multivariate analysis only HYAL-1 staining independently predicted recurrence with an accuracy of 81.8% (p <0.001). In prostatectomy specimens only HYAL-1 staining correlated with staining in biopsy specimens (Spearman rho = 0.72, p = 0.0002) and predicted biochemical recurrence.
To our knowledge this is the first report that HYAL-1 staining in biopsy specimens is an independent predictor of biochemical recurrence. This may be useful when selecting treatment.
分子标志物有助于前列腺特异性抗原、活检Gleason评分和临床分期,以提供有关前列腺癌进展的准确信息。前列腺切除标本中的透明质酸酶1(HYAL-1)和透明质酸染色可预测生化复发。我们研究了活检标本中的透明质酸和HYAL-1染色是否能预测生化复发,并与匹配的前列腺切除标本中的染色相关。
从多个中心的61例临床局限性前列腺癌患者中获取活检和前列腺切除标本,其中23例发生生化复发(第1组),38例未发生生化复发(第2组)。平均随访时间为103.1个月。分别使用生物素化透明质酸结合蛋白和抗HYAL-1抗体进行透明质酸和HYAL-1染色。根据染色强度和面积,染色分级为0至300。
HYAL-1和透明质酸分别在肿瘤细胞和基质中表达。在活检标本中,第1组的HYAL-1和透明质酸表达高于第2组(分别为203.9和182.1,对比48.8和87.0,p<0.0001)。单因素分析显示,透明质酸、HYAL-1、活检Gleason评分和前列腺特异性抗原显著预测生化复发(p<0.001)。多因素分析显示,只有HYAL-1染色独立预测复发,准确率为81.8%(p<0.001)。在前列腺切除标本中,只有HYAL-1染色与活检标本中的染色相关(Spearman秩相关系数=0.72,p=0.0002)并预测生化复发。
据我们所知,这是第一份关于活检标本中HYAL-1染色是生化复发独立预测因子的报告。这在选择治疗方法时可能有用。